CN208270585U - ST2 Test paper and detection kit - Google Patents
ST2 Test paper and detection kit Download PDFInfo
- Publication number
- CN208270585U CN208270585U CN201721851158.5U CN201721851158U CN208270585U CN 208270585 U CN208270585 U CN 208270585U CN 201721851158 U CN201721851158 U CN 201721851158U CN 208270585 U CN208270585 U CN 208270585U
- Authority
- CN
- China
- Prior art keywords
- pad
- coated film
- label
- sample
- detection zone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The utility model relates to a kind of ST2 Test paper and detection kit, ST2 Test paper includes bottom plate, sample pad, label pad, coated film and absorption pad.Label pad, coated film and absorption pad are successively set on bottom plate from one end of bottom plate to the other end, sample pad partly overlaps with label pad, label pad partly overlaps with coated film, coated film partly overlaps with absorption pad, coated film is equipped with detection zone and Quality Control region, and label pad can combine different ST2 epitopes from detection zone.Above-mentioned ST2 Test paper, can immediately, fast and accurately quantitative detection ST2, can be used in the diagnosis, treatment and prognosis of early stage heart failure.
Description
Technical field
The utility model relates to technical field of immunoassay more particularly to a kind of ST2 Test paper and detection kits.
Background technique
Heart failure (heart failure, HF) is myocardial damage caused due to various reasons, causes myocardial structural
With the variation of function, lead to ventricular filling and (or) penetrate the decline of blood ability, cardiac output is reduced, and cannot be the generation of body tissue
It thanks and enough energy is provided.Wherein chronic heart failure (Chronic heart failure, CHF) refers to since ventricle is born
Heart failure caused by long-term capacity and pressure load continues a kind of existing state, it can be chronically at stable state,
But it can also sharply deteriorate and even result in death, belong to clinical critical illness, case fatality rate is high, it has also become cardiovascular patient is dead
The main reason for.The diagnosis of heart failure is mainly according to clinical manifestation, however, heart failure clinically may be because of mild symptoms, obesity
Unobvious, merging pulmonary disease of caused sign etc. is difficult to diagnose, and lacks sensitivity and specific all high laboratory ginseng in addition
Index is examined, diagnosis and the judgement of severity extent are unfavorable for.Therefore, sensitivity and specificity height, the objective reliable reflection heart are found
The index to decline is always the hot issue of clinician's concern.
Traditional method is to characterize heart failure, NT- by detecting the level of Amino-terminal B-type natriuretic peptide (NT-proBNP)
ProBNP has become the clinically diagnosis most widely used marker of heart failure.However NT-proBNP concentration is vulnerable to year in blood plasma
The factors such as age, gender, obesity, left ventricular hypertrophy, right ventricle's high load capacity influence, it is therefore desirable to further seek new biological marker
Object supplements the deficiency of NT-proBNP, improves the accuracy of clinical diagnosis heart failure.
In recent years, new heart failure Testing index such as 2 albumen of growth stimulation expressing gene (ST2) attracts much attention.ST2
Albumen is one of interleukin-1 receptor family member.There are 4 kinds of hypotypes, ST2L, sST2, ST2Vs and ST2LV by ST2.Wherein ST2L
It is made of 3 transmembrane segment, cytoplasmic domain and immunoglobulin domains parts, structure and interleukins (IL-1) phase
Seemingly.SST2 lacks all endochylema and transmembrane domain compared with ST2L, but contains unique C-terminal sequence, by there is 9 ammonia
Base acid composition.ST2V and ST2VL is 2 splice variants of ST2.The transmembrane structure that ST2 removes ST2L is ST2LV, and ST2V
3rd immunoglobulin sequences are removed by ST2, and form it into the hydrophobic tail with special construction in C-terminal montage and
At.
Soluble 2 albumen of growth stimulation expressing gene (ST2) is one kind that release is generated by the induction of mechanical stress
Protein can cause the generation of IL-33 and ST2 to be released in the case where fibroblast and cardiac muscle cell are stretched by mechanicalness
It puts, the horizontal of serum sST2 is caused to increase.The degree of heart failure is heavier, and mechanical tension suffered by ventricle is bigger, and sST2 generates release
More, serum sST2 concentration is higher.In the case where vascular capacitance load and excessive pressure load, sST2 is largely released into blood,
The effect of antagonism IL-33, so as to cause myocardial hypertrophy, cardiac ejection fraction reduction, atrial ventricle's expansion etc..
Clinically the detection method of ST2 is mainly enzyme-linked immunization (ELISA) at present, however, there are operating procedures by ELISA
It is cumbersome, time-consuming, need professional, and the influence factor of operating process is more, easily cause false positive and false negative result etc.
Deficiency, these disadvantages limit it in the extensive use of field of fast detection.
To sum up, lack the product for immediately, fast and accurately detecting ST2 at present.
Utility model content
Based on this, it is necessary to provide a kind of with the Test paper for immediately, fast and accurately detecting ST2 and detection examination
Agent box.
A kind of ST2 Test paper, including bottom plate, sample pad, label pad, coated film and absorption pad, the sample pad, institute
It states label pad, the coated film and the absorption pad and is successively set on the bottom plate from one end of the bottom plate to the other end
On, the sample pad partly overlaps with the label pad, and the label pad partly overlaps with the coated film, the coated film with
The absorption pad partly overlaps, and the coated film is equipped with detection zone and Quality Control region, the label pad and the detection zone
Domain can combine different ST2 epitopes.
In one embodiment, the label pad be the first ST2 monoclonal antibody marked equipped with fluorescent microsphere and
The label pad of the Avidin of fluorescent microsphere label, the coated film are equipped with the 2nd ST2 monoclonal antibody detection zone and affine
Plain antibody Quality Control region, the label pad can combine different ST2 tables from the 2nd ST2 monoclonal antibody detection zone
Position.
In one embodiment, the partial size of the fluorescent microsphere is 100nm~500nm.
In one embodiment, the excitation wavelength of the fluorescent microsphere is 310nm~550nm, the fluorescent microsphere
Launch wavelength is 340nm~620nm.
In one embodiment, there is gap, and the detection zone between the detection zone and the Quality Control region
Domain is located at close to one end of the label pad, and the Quality Control region is located at close to one end of the absorption pad.
In one embodiment, the detection zone is linear, and the Quality Control region is linear, the detection zone from
First direction crosses over the coated film, and the first direction is that can intersect with the line of the label pad to the absorption pad
The coated film is crossed over from second direction in direction, the Quality Control region, and the second direction is can be with the label pad to institute
State the direction of the line intersection of absorption pad.
In one embodiment, the first direction is the side vertical with the line of the label pad to the absorption pad
Be the direction vertical with the line of the label pad to the absorption pad to, the second direction, the detection zone with it is described
Quality Control region is arranged in parallel, and the spacing in the gap between the detection zone and the Quality Control region is 4mm~8mm.
In one embodiment, the sample pad is the sample pad equipped with mouse anti-human RBC's antibody.
In one embodiment, the sample pad length Chong Die with the label pad is 1mm~5mm, the label
Padding length Chong Die with the coated film is 1mm~5mm, the coated film length Chong Die with the absorption pad for 1mm~
5mm。
A kind of ST2 detection kit, which is characterized in that including ST2 Test paper described in any of the above embodiments.
Above-mentioned ST2 Test paper includes bottom plate, sample pad, label pad, coated film and absorption pad, and coated film is equipped with inspection
Different ST2 epitopes can be combined from detection zone by surveying region and Quality Control region, label pad.In use, by sample to be detected
It is added in the sample pad of above-mentioned ST2 Test paper, if containing ST2 (antigen) in test sample, ST2 antigen is under chromatography effect
Pass sequentially through label pad and coated film.Label pad can combine different ST2 epitopes from the detection zone of coated film, so that
The combination effect of ST2 antigen is more preferable, avoids influencing each other, and improves the accuracy of detection.Above-mentioned ST2 Test paper detection operation letter
It is single, can immediately, fast and accurately detect ST2, provided a great convenience for clinical use.It can be used in early stage heart failure
Diagnosis, treatment and prognosis, suitable for carrying out extensively in each medical institutions.
Detailed description of the invention
Fig. 1 is the structural schematic diagram of the ST2 Test paper of an embodiment；
Fig. 2 is the exploded view of ST2 Test paper shown in FIG. 1.
Specific embodiment
The utility model is more fully retouched below with reference to relevant drawings for the ease of understanding the utility model,
It states.The preferred embodiment of the utility model is given in attached drawing.But the utility model can come in many different forms
It realizes, however it is not limited to embodiment described herein.On the contrary, purpose of providing these embodiments is makes to the utility model
The understanding of disclosure is more thorough and comprehensive.
It should be noted that it can directly on the other element when element is referred to as " being fixed on " another element
Or there may also be elements placed in the middle.When an element is considered as " connection " another element, it, which can be, is directly connected to
To another element or it may be simultaneously present centering elements.Term as used herein " vertical ", " horizontal ", " left side ",
" right side " and similar statement are for illustrative purposes only.
Unless otherwise defined, all technical and scientific terms used herein are led with the technology for belonging to the utility model
The normally understood meaning of the technical staff in domain is identical.Terminology used in the description of the utility model herein only be
The purpose of description specific embodiment, it is not intended that in limitation the utility model.Term " and or " used herein includes
Any and all combinations of one or more related listed items.
As depicted in figs. 1 and 2, the ST2 Test paper 10 of an embodiment, including bottom plate 100, sample pad 200, label pad
300, coated film 400 and absorption pad 500.Sample pad 200, label pad 300, coated film 400 and absorption pad 500 are from bottom plate
100 one end is successively set on bottom plate 100 to the other end.Sample pad 200 partly overlaps with label pad 300, label pad 300 with
Coated film 400 partly overlaps, and coated film 400 partly overlaps with absorption pad 500.Coated film 400 is equipped with detection zone 401 and matter
Region 402 is controlled, and label pad 300 can combine different ST2 epitopes from detection zone 401.
Above-mentioned ST2 Test paper 10, label pad 300 can combine different ST2 from the detection zone 401 of coated film 400
Epitope.In use, sample to be detected is added in the sample pad 100 of above-mentioned ST2 Test paper 10, if containing in test sample
ST2 (antigen), then ST2 antigen passes sequentially through label pad 300 and coated film 400 under chromatography effect.Label pad 300 and coating
The detection zone 401 of film 400 can avoid mutual shadow so that the combination effect of ST2 antigen is more preferable in conjunction with different ST2 epitopes
It rings, improves the accuracy of detection.
Specifically, label pad 300 is the first ST2 monoclonal antibody 310 marked equipped with fluorescent microsphere and fluorescent microsphere
The label pad of the Avidin 320 of label.Coated film 400 is equipped with 410 detection zone of the 2nd ST2 monoclonal antibody and Avidin is anti-
420 Quality Control region of body.Label pad 300 can combine different ST2 epitopes from 420 detection zone of the 2nd ST2 monoclonal antibody.
The first monoclonal antibody and the 2nd ST2 monoclonal in first ST2 monoclonal antibody 310 of fluorescent microsphere label is anti-
Body 410 is directed to different ST2 epitopes respectively, and the ST2 in sample can be mono- with the first ST2 monoclonal antibody and the 2nd ST2 respectively
Clonal antibody combines and forms double-antibody sandwich compound, more preferable in conjunction with effect, improves the accuracy of detection.
The first ST2 monoclonal antibody is provided by Fitzgerald company in present embodiment, production number 10-2321.The
Two ST2 monoclonal antibodies are provided by Fitzgerald company, production number 10-2322.
In present embodiment, ST2 Test paper 10 is in a strip shape, and in other embodiments, ST2 Test paper 10 can also
In other different shapes, such as round, triangle etc..
Specifically, sample pad 200, label pad 300, coated film 400 and absorption pad 500 are from one end of bottom plate 100 to another
One end is successively set on bottom plate 100, and the length Chong Die with label pad 300 of sample pad 200 is 1mm~5mm.Label pad 300 with
The length that coated film 400 is overlapped is 1mm~5mm.The length Chong Die with absorption pad 500 of coated film 400 is 1mm~5mm.This knot
The ST2 Test paper 10 of structure can be under the action of absorption pad 500 successively when sample to be detected is added in sample pad 200
By label pad 300 and coated film 400, and according to the change in fluorescence of the detection zone of coated film 400 401 and Quality Control region 402,
Detect the content of ST2 in sample to be detected.
Further, sample pad 200, label pad 300, coated film 400 and absorption pad 500 successively overlap.Sample pad 200
With the lap of label pad 300, sample pad 200 is on surface.The lap of label pad 300 and coated film 400, label pad
300 on surface.The lap of coated film 400 and absorption pad 500, absorption pad 500 is on surface.This design is so as to be detected
Sample successively passes through label pad 300 and coated film 400 from sample pad 200s, flows more smooth.
Specifically, bottom plate 100 can be PCV bottom plate (polyvinyl chloride bottom plate) or glass substrate etc..In present embodiment, bottom
Plate 100 is PCV bottom plate, and PCV bottom plate is frivolous, has good corrosion resistance and good waterproof performance, avoid antibody with
And sample leakage to be detected.
In one embodiment, sample pad 200 is the sample pad equipped with mouse anti-human RBC's antibody 210.Mouse is anti-human red
Cell antibody 210 can be inhaled in conjunction with red blood cell, when sample to be detected is blood sample, be enabled in sample pad 200
Red blood cell adhesion, the detection zone 401 that will not be moved to ST2 antigen on coated film 400 and Quality Control region 402.Reduce inspection
Red blood cell influences fluorescence intensity when survey, improves the sensitivity of detection.
Further, casein, PEG (polyethylene glycol) etc. are additionally provided in sample pad 200, so that non-in sample to be detected
The substance of specificity is combined and is rested in sample pad 200, the detection zone 401 that will not be moved to ST2 antigen on coated film 400
And Quality Control region 402, improve the sensitivity of detection.
Specifically, in the first ST2 monoclonal antibody 310 of fluorescent microsphere label, fluorescent microsphere and the first ST2 monoclonal are anti-
The ratio of body is 0.1mg~1.0mg:1mL.In the Avidin 320 of fluorescent microsphere label, the ratio of fluorescent microsphere and Avidin is
0.1mg~1.0mg:1mL.
Specifically, the Avidin 320 of the first ST2 monoclonal antibody 310 of fluorescent microsphere label and fluorescent microsphere label
In the partial size of fluorescent microsphere be 100nm~500nm, the excitation wavelength of fluorescent microsphere is 310nm~550nm, fluorescent microsphere
Launch wavelength is 340nm~620nm.The partial size of fluorescent microsphere is smaller, and can shine under conditions of certain exciting light, root
According to the content of ST2 in luminous intensity quantitative detection sample to be tested.
Specifically, by the first ST2 monoclonal antibody 310 of fluorescent microsphere label and the Avidin 320 of fluorescent microsphere label
It is mixed to form and forms label pad treatment fluid with diluted, then label pad treatment fluid is sprayed into label pad 300.Mark
The percentage by volume of the first ST2 monoclonal antibody 310 of fluorescent microsphere label is 5%~20% in note pad treatment fluid, and fluorescence is micro-
The percentage by volume of the Avidin 320 of ball label is 0.5%~5%.The discharge rate of label pad treatment fluid is 3 μ L/ in label pad 300
The μ of cm~6 L/cm.
In one embodiment, 400 nitrocellulose filter of coated film, on coated film 400, detection zone 401 and matter
Controlling has gap between region 402.And detection zone 401 is located at close to one end of label pad 300, Quality Control region 402, which is located at, to be leaned on
One end of nearly absorption pad 500.Detection zone 401 and the interval of Quality Control region 402 are arranged, and prevent fluorescence cross from polluting, improve detection
Accuracy.Detection zone 401 is close to label pad 300 simultaneously, so that sample to be detected first passes through detection zone 401, such as sample
Contain ST2 antigen in this, is then first combined in detection zone 401 with the 2nd ST2 monoclonal antibody 410 to form double-antibody sandwich and answer
It closes object and rests in detection zone 401, reduce contaminated probability.
Specifically, detection zone 401 is linear (detection line), and Quality Control region 402 is linear (nature controlling line).Detection zone
401 cross over coated film 400 from first direction.First direction is the side that can intersect with the line of label pad 300 to absorption pad 500
To.Coated film 400 is crossed over from second direction in Quality Control region 402, and second direction 400 is can be with label pad 300 to absorption pad 500
Line intersection direction.Such as detection zone 401 and Quality Control region 402 across or be inclined cross coated film 400 so that from label pad
300 to absorption pad 500, sample to be detected must region 401 and Quality Control region 402 after testing, prevent missing inspection, false yin occur
The result of property.
In one embodiment, as shown in Figure 1, detection zone 401 and Quality Control region 402 are across coated film 400.I.e.
One direction is the direction vertical with the line of label pad 300 to absorption pad 500, and second direction is also and label pad 300 to absorption
The vertical direction of the line of pad 500, detection zone 401 are arranged in parallel with Quality Control region 402.This design can reduce detection zone
The dosage of antibody on domain 401 and Quality Control region 402, save the cost.
Further, the spacing in the gap between detection zone 401 and Quality Control region 402 is 4mm~8mm.
In one embodiment, the Avidin antibody 420 on Quality Control region 402 is rabbit-anti Avidin antibody.Rabbit-anti parent
With plain antibody and Avidin excellent bonding performance, non-specific binding is few.
Specifically, absorption pad 500 is the blotting paper with good water absorbing properties, and sample to be detected is being absorbed
Successively pass through label pad 300 and coated film 400 from sample pad 200s under the attraction of pad 500.
Specifically, sample pad 200, label pad 300, coated film 400 are sequentially mutually pasted to overlap joint on bottom plate 100 and are inhaled
Water cushion 500 obtains test paper plate, and the test strips of 4mm width are cut into according to cutting requirement, obtains ST2 Test paper 10.
In present embodiment, in use, sample to be detected is added in the sample pad 200 of above-mentioned ST2 Test paper 10.
And successively pass through label pad 300 and coated film 400 from sample pad 200s under the attraction of absorption pad 500.If test sample
In contain ST2 (antigen), then ST2 antigen chromatography effect under in label pad 300 fluorescent microsphere label the first ST2 Dan Ke
Grand antibody 310 combines and forms compound.The compound is moved to the detection zone 401 on coated film 400 under chromatography effect, and
It is combined with the 2nd ST2 monoclonal antibody 410 in detection zone 401, forms double-antibody sandwich compound.Double-antibody sandwich is compound
Object is gathered at detection zone 401, and by light source activation, fluorescent microsphere releases the transmitting light of respective wavelength.ST2 is anti-in sample
Original content is higher, and the intensity that detection zone emits light is higher, converts optical signal into digital signal by fluorescence detecting system, with
Concentration point is abscissa, and detection zone signal value is that ordinate draws standard curve than nature controlling line signal value (T/C), so as to standard
Determine the concentration for calculating ST2 in sample of amount.
The Avidin 320 of fluorescent microsphere label in label pad 300 is moved to the Quality Control region 402 on coated film 400, with
Avidin antibody 420 combine, formed fluorescent microsphere-Avidin-antibody complex, fluorescent microsphere-Avidin-antibody complex by
To light source activation, fluorescent microsphere releases the transmitting light of respective wavelength.Therefore under normal circumstances, no matter sample to be detected whether
Containing ST2, should all there be fluorescence in Quality Control region 402, illustrate that testing result is invalid if 402 unstressed configuration of Quality Control region, avoid vacation
Negative or false positive testing result.
Specifically, in an embodiment, using soluble raw in ST2 Test paper quantitative detection blood sample as shown in Figure 1
The concentration of long stimulation 2 albumen of expressing gene, the specific steps are as follows:
(1) Specification Curve of Increasing
By ST2 antigen with negative plasma be configured to 200ng/mL, 100ng/mL, 50ng/mL, 25ng/mL, 12.5ng/mL,
6.25ng/mL, 3.12ng/mL, 0ng/mL, with a batch of reagent, each concentration point is tested 6 times.With detection zone (T
Band), the fluorescence intensity ratio of Quality Control region (C band) be ordinate, ST2 reference material concentration is abscissa, establishes equation and is fitted
At standard curve, bent information will be marked and write in ID chip with burn recording software.
(2) detection of sample:
Detector bar is taken out from kit, after tearing packaging of aluminium foil bag, is laid flat detector bar, is balanced 5 minutes, take 100 μ L samples
In this addition well, room temperature is protected from light 15 minutes.By ID chip be inserted into fluorescence detector, will test card insertion enter luminoscope insert
Bayonet is clicked " test ", and instrument calculates the concentration of ST2 in sample to be tested by analyzing software automatically.
(3) it is tried with the Soluble growth of U.S. Critical diagnostics company stimulation 2 Protein Detection of expressing gene
Agent box (enzyme linked immunosorbent assay) carries out correlation comparison.
It is stimulated and is expressed using the Soluble growth of test strips of the invention and U.S. Critical diagnostics company
2 protein detection kit of gene detects 40 human serum samples, and measurement result is shown, in this test strips detection range
(3.0~200ng/mL), the correlation R of two kinds of reagents2> 0.95 (y=0.978x+1.168).
These results suggest that the sensitivity that the ST2 Test paper 10 of the present embodiment detects is good, accuracy is good.
To sum up, the ST2 Test paper 10 of the present embodiment at least has the following beneficial effects: (1) detection zone 401 and Quality Control
Region 402 is spaced, and the luminous intensity of detection zone 401 depends on the ST2 content in sample, Quality Control region 402 it is luminous
Intensity depends on Avidin, and the two does not interfere with each other and influences.The mode that T/C value can be used is quantified, and ensure that test result
Accuracy.(2) the first ST2 monoclonal antibody 310 of the fluorescent microsphere label in label pad 300, with 400 detection zone of coated film
The 2nd ST2 monoclonal antibody 410 on domain 401, the first ST2 monoclonal antibody and the 2nd ST2 monoclonal antibody point in the two
Safety pin to different ST2 epitopes, ST2 in sample can respectively with the first ST2 monoclonal antibody and the 2nd ST2 monoclonal antibody
It is more preferable in conjunction with effect in conjunction with formation double-antibody sandwich compound, improve the accuracy of detection.(3) in use, it is easy to operate, at
This is low.Concentration is used down to the ST2 (Soluble growth stimulates 2 albumen of expressing gene) of 1ng/mL in detectable blood sample
Detector is not necessarily to professional operator, testing result can be obtained within 15 minutes.
A kind of ST2 detection kit, including above-mentioned ST2 Test paper 10.
A plurality of ST2 Test paper 10 can be contained in the detection box.
Further, ST2 Test paper 10 can also use packaging of aluminium foil bag, convenient for storage and transport.
Above-mentioned ST2 detection kit can immediately, fast and accurately quantitative detection ST2, realize that single part of ST2 is quantitative
Detection, provides a great convenience for clinical use.It can be used in the diagnosis, treatment and prognosis of early stage heart failure, be suitable for each
Medical institutions carry out extensively.
Each technical characteristic of embodiment described above can be combined arbitrarily, for simplicity of description, not to above-mentioned reality
It applies all possible combination of each technical characteristic in example to be all described, as long as however, the combination of these technical characteristics is not deposited
In contradiction, all should be considered as described in this specification.
Above-described embodiments merely represent several embodiments of the utility model, the description thereof is more specific and detailed,
But it cannot be understood as the limitations to utility model patent range.It should be pointed out that for the common skill of this field
For art personnel, without departing from the concept of the premise utility, various modifications and improvements can be made, these are belonged to
The protection scope of the utility model.Therefore, the scope of protection shall be subject to the appended claims for the utility model patent.
Claims (7)
1. a kind of ST2 Test paper, which is characterized in that described including bottom plate, sample pad, label pad, coated film and absorption pad
Sample pad, the label pad, the coated film and the absorption pad are successively set on from one end of the bottom plate to the other end
On the bottom plate, the sample pad partly overlaps with the label pad, and the sample pad is located at the surface of the label pad, described
Label pad partly overlaps with the coated film, and the coated film partly overlaps with the absorption pad, and the coated film is equipped with inspection
Region and Quality Control region are surveyed, the label pad is the first ST2 monoclonal antibody marked equipped with fluorescent microsphere and fluorescent microsphere
The label pad of the Avidin of label, the coated film are equipped with the 2nd ST2 monoclonal antibody detection zone and Avidin antibody matter
Region is controlled, the label pad can be in conjunction with different ST2 epitopes, the inspection from the 2nd ST2 monoclonal antibody detection zone
Survey region it is linear, the Quality Control region is linear, the detection zone from first direction cross over the coated film, described first
Direction is direction that can be vertical with the line of the label pad to the absorption pad, and the Quality Control region is crossed over from second direction
The coated film, the second direction are direction that can be vertical with the line of the label pad to the absorption pad, the inspection
It surveys region to be arranged in parallel with the Quality Control region, the sample pad length Chong Die with the label pad is 1mm~5mm, described
The label pad length Chong Die with the coated film is 1mm~5mm, and the coated film length Chong Die with the absorption pad is 1mm
~5mm.
2. ST2 Test paper according to claim 1, which is characterized in that the partial size of the fluorescent microsphere be 100nm~
500nm。
3. ST2 Test paper according to claim 1 or claim 2, which is characterized in that the excitation wavelength of the fluorescent microsphere is
310nm~550nm, the launch wavelength of the fluorescent microsphere are 340nm~620nm.
4. ST2 Test paper according to claim 1, which is characterized in that between the detection zone and the Quality Control region
With gap, and the detection zone is located at close to one end of the label pad, and the Quality Control region is located at close to the absorption
One end of pad.
5. according to claim 1 or the 4 ST2 Test papers, which is characterized in that the detection zone and the Quality Control region it
Between gap spacing be 4mm~8mm.
6. ST2 Test paper according to claim 1, which is characterized in that the sample pad is anti-equipped with mouse anti-human RBC
The sample pad of body.
7. a kind of ST2 detection kit, which is characterized in that including ST2 Test paper as described in any one of claims 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201721851158.5U CN208270585U (en) | 2017-12-26 | 2017-12-26 | ST2 Test paper and detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201721851158.5U CN208270585U (en) | 2017-12-26 | 2017-12-26 | ST2 Test paper and detection kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN208270585U true CN208270585U (en) | 2018-12-21 |
Family
ID=64673565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201721851158.5U Active CN208270585U (en) | 2017-12-26 | 2017-12-26 | ST2 Test paper and detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN208270585U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113311173A (en) * | 2021-07-28 | 2021-08-27 | 南京申基医药科技有限公司 | Combined detection test strip for detecting ST2 and Galectin-3 antibodies in blood sample, preparation method and kit |
-
2017
- 2017-12-26 CN CN201721851158.5U patent/CN208270585U/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113311173A (en) * | 2021-07-28 | 2021-08-27 | 南京申基医药科技有限公司 | Combined detection test strip for detecting ST2 and Galectin-3 antibodies in blood sample, preparation method and kit |
| CN113311173B (en) * | 2021-07-28 | 2022-08-26 | 南京申基医药科技有限公司 | Combined detection test strip for detecting ST2 and Galectin-3 antibodies in blood sample for improving detection accuracy, preparation method and kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108254562B (en) | Detect time-resolved fluoroimmunoassay chromatograph test strip, the kit and preparation method thereof of MYO | |
| US7374950B2 (en) | Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients | |
| CN108398557A (en) | A kind of myeloperoxidase fluorescence immune chromatography test paper bar and test card | |
| US10101326B2 (en) | Method for determining a marker in small volume of a sample of a bodily fluid | |
| CN104865387A (en) | Immunofluorescence test strip for rapidly and quantitatively detecting ST2 (growth stimulation expressed gene 2) and NT-proBNP (N-terminal-pro-B-type-Natriuretic Peptide) and preparation method of immunofluorescence test strip | |
| CN108333374A (en) | C reactive protein, serum amyloid A protein immunochromatography quantify combined detection test paper and preparation method thereof | |
| CN107219371A (en) | PCT fluorescent micro-ball immune chromatography detection reagent cards and preparation method thereof | |
| CN106918708A (en) | A kind of competition law turbid kit of latex enhancing immune transmittance for detecting insulin | |
| CN107328942A (en) | A kind of fluorogenic quantitative detection PAPP A immunochromatography reagent bar and preparation method thereof | |
| CN106771143A (en) | The preparation method of the prostate cancer antigen immuno-chromatographic test paper strip of low concentration antibody is efficiently fixed based on hydrophobin | |
| CN204287206U (en) | NT-proBNP precursor immunochromatographiassay assay quantitative detection test paper | |
| CN104215757B (en) | Biological fluid sample quantitative test device and its detection method | |
| CN208270585U (en) | ST2 Test paper and detection kit | |
| CN208367017U (en) | Serum amyloid A protein immunochromatographiassay assay quantitative detection test paper | |
| EP3802591A1 (en) | Antibody pairs for use in a rapid influenza b diagnostic test | |
| CN201203618Y (en) | Immune colloidal gold test card for new castle disease virus | |
| CN101285839A (en) | Quick detection method for newcastle disease virus and its immune colloidal gold test card | |
| CN108226468A (en) | A kind of test strips for detecting NT-proBNP and preparation method and application | |
| US7109023B2 (en) | Immunossay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients | |
| CN207081737U (en) | Immune chromatographic semiquantitative test paper bar, kit | |
| CN110873801A (en) | Thyroid hormone immunochromatography test strip and preparation method and kit thereof | |
| CN206362809U (en) | The Test paper component of human growth and differentiation factor 7 15 | |
| CN110346570A (en) | Detect the colloidal gold kit and method of diabetic nephropathy biomarker | |
| CN208537565U (en) | C reactive protein, serum amyloid A protein immunochromatography quantify combined detection test paper | |
| CN204287192U (en) | Myeloperoxidase immunochromatographiassay assay quantitative detection test paper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |